GlassScriptPhysician profile
Daniel B Salvas
NPI 1811912140
$24,683.14
in general payments reported to CMS, 2019-2025
38 companies · $7,435 in 2025
The $7,435 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $104 · 2022: $241 · 2023: $698 · 2024: $16K · 2025: $7,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $22K · Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $22,071.43 |
| Food and Beverage | $1,992.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Central Indiana Urs Consumables, LLC | $22,071.43 | 2024-2025 | Dornier Medtech, Cvac Aspiration System, Dornier Medtech |
| Dendreon Pharmaceuticals LLC | $240.36 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $230.96 | 2020-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $211.39 | 2023-2025 | Gemtesa, Orgovyx |
| Genzyme Corporation | $190.60 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.29 | 2019-2025 | |
| Pfizer INC. | $159.72 | 2019-2025 | |
| Astellas Pharma US INC | $150.39 | 2019-2024 | Xtandi, Myrbetriq |
| Amgen INC. | $108.31 | 2019-2022 | |
| Tolmar, INC. | $102.37 | 2023-2025 | Jatenzo, Eligard |
| Progenics Pharmaceuticals, INC. | $89.81 | 2023-2025 | Pylarify |
| Sun Pharmaceutical Industries INC. | $81.10 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $78.90 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Laborie Medical Technologies Corp. | $74.02 | 2024-2025 | Urgent PC Neuromodulation System |
| Urogen Pharma, INC. | $71.42 | 2023-2024 | Jelmyto |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$47,040.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Salvas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.